Takeda Pharmaceutical Co. (NYSE:TAK) Shares Bought by Sequoia Financial Advisors LLC

Sequoia Financial Advisors LLC boosted its position in shares of Takeda Pharmaceutical Co. (NYSE:TAK - Free Report) by 70.3% in the first quarter, according to the company in its most recent Form 13F filing with the SEC. The fund owned 64,599 shares of the company's stock after acquiring an additional 26,656 shares during the quarter. Sequoia Financial Advisors LLC's holdings in Takeda Pharmaceutical were worth $961,000 at the end of the most recent reporting period.

Other institutional investors also recently bought and sold shares of the company. Inscription Capital LLC purchased a new position in shares of Takeda Pharmaceutical in the first quarter valued at about $303,000. FNY Investment Advisers LLC bought a new stake in Takeda Pharmaceutical during the 1st quarter valued at approximately $37,000. QRG Capital Management Inc. lifted its holdings in Takeda Pharmaceutical by 17.4% in the 1st quarter. QRG Capital Management Inc. now owns 386,928 shares of the company's stock worth $5,754,000 after purchasing an additional 57,284 shares in the last quarter. Sagespring Wealth Partners LLC bought a new position in shares of Takeda Pharmaceutical during the first quarter worth $162,000. Finally, Fifth Third Bancorp lifted its stake in Takeda Pharmaceutical by 85.5% in the 1st quarter. Fifth Third Bancorp now owns 5,232 shares of the company's stock worth $78,000 after purchasing an additional 2,411 shares in the last quarter. Institutional investors own 9.17% of the company's stock.

Takeda Pharmaceutical Stock Performance

Shares of TAK stock traded up $0.13 during mid-day trading on Thursday, reaching $15.55. The stock had a trading volume of 1,649,041 shares, compared to its average volume of 1,973,724. Takeda Pharmaceutical Co. has a 1-year low of $12.80 and a 1-year high of $15.55. The firm has a market cap of $49.48 billion, a price-to-earnings ratio of 70.69 and a beta of 0.23. The company has a current ratio of 1.01, a quick ratio of 0.52 and a debt-to-equity ratio of 0.57. The business's fifty day moving average is $14.85 and its 200-day moving average is $14.29.

Takeda Pharmaceutical (NYSE:TAK - Get Free Report) last issued its earnings results on Thursday, May 8th. The company reported $0.16 earnings per share (EPS) for the quarter, missing the consensus estimate of $0.24 by ($0.08). The business had revenue of $7.34 billion for the quarter, compared to analysts' expectations of $8.02 billion. Takeda Pharmaceutical had a return on equity of 10.64% and a net margin of 2.36%. On average, research analysts forecast that Takeda Pharmaceutical Co. will post 1.64 earnings per share for the current year.

Wall Street Analyst Weigh In

Separately, Morgan Stanley raised shares of Takeda Pharmaceutical from an "equal weight" rating to an "overweight" rating in a research note on Wednesday, April 2nd.

Takeda Pharmaceutical Profile

Takeda Pharmaceutical Company Limited engages in the research, development, manufacture, marketing, and out-licensing of pharmaceutical products in Japan and internationally. It offers pharmaceutical products in the areas of gastroenterology, rare diseases, plasma derived therapies, immunology, oncology, and neuroscience.